A Phase 1 Multiple Ascending Dose Study of BMS-833923 in Subjects With Advanced or Metastatic Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2014
At a glance
- Drugs BMS 833923 (Primary)
- Indications Basal cell cancer; Basal cell nevus syndrome; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 14 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 22 Aug 2013 Planned end date changed from 1 Jul 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.